Cyclodextrin-Based Delivery Systems for Anticancer Drugs, 2nd Edition

Dear Colleagues,

Malignant diseases are one of the most powerful diseases of the current century, representing a major cause of death at a global level. Even though anticancer research and drug discovery continuously increase the therapeutic options, chemotherapy remains a method with many drawbacks due to poor bioavailability, side effects, drug resistance, and target specificity.

In addition to the screening of synthetic molecules with anticancer potential, natural compounds represent a valuable alternative to the limitations of conventional chemotherapy. Natural compounds also face drawbacks that limit their utilization, such as poor water solubility, low dissolution rate, bioavailability, and increased sensitivity to degradation and inactivation. 

Today, cyclodextrins are considered valuable pharmaceutical excipients due to their ability to partly or completely include a drug molecule, thus improving the unfavorable physicochemical and the biological properties of the hosted molecule. Moreover, the protection and, especially, the controlled release of various organic compounds are carried out almost exclusively via encapsulation.

Currently, the development of improved formulations based on natural and synthetic compounds with increased bioavailability and stability, along with dose reduction and the reduction in adverse effects, represents a topical issue to be explored.

This Special Issue will bring together recent data regarding the role of cyclodextrins in developing improved delivery systems containing anticancer compounds. We welcome reviews and original research on all aspects of the influence of cyclodextrin complexation on the physicochemical and biological properties of anticancer drugs.

Dr. Cristina Trandafirescu
Dr. Iulia Pinzaru
Dr. Denisa Laura Cîrcioban
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cyclodextrins
• delivery systems
• anticancer compounds
• natural compounds
• bioavailability
• stability

• Cyclodextrin-Based Delivery Systems for Anticancer Drugs in Pharmaceutics (9 articles)